Uli Hacksell

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Lehmann Fredrik; Currier Erika A; Clemons Bryan; Hansen Lars K; Olsson Roger; Hacksell Uli; Luthman Kristina
Novel and potent small-molecule urotensin II receptor agonists.
Lund Birgitte W; Knapp Anne Eeg; Piu Fabrice; Gauthier Natalie K; Begtrup Mikael; Hacksell Uli; Olsson Roger
Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
Nordstrom Anna-Lena; Mansson Mattias; Jovanovic Hristina; Karlsson Per; Halldin Christer; Farde Lars; Vanover Kimberly E; Hacksell Uli; Brann Mark R; Davis Robert E; Weiner David M
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Uli Hacksell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lehmann Fredrik; Currier Erika A; Clemons Bryan; Hansen Lars K; Olsson Roger; Hacksell Uli; Luthman Kristina
Novel and potent small-molecule urotensin II receptor agonists.
Bioorganic & medicinal chemistry 2009;17(13):4657-65.
2009: Lund Birgitte W; Knapp Anne Eeg; Piu Fabrice; Gauthier Natalie K; Begtrup Mikael; Hacksell Uli; Olsson Roger
Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
Journal of medicinal chemistry 2009;52(6):1540-5.
2008: Nordstrom Anna-Lena; Mansson Mattias; Jovanovic Hristina; Karlsson Per; Halldin Christer; Farde Lars; Vanover Kimberly E; Hacksell Uli; Brann Mark R; Davis Robert E; Weiner David M
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2008;11(2):163-71.
2008: Bakker Remko A; Jongejan Aldo; Sansuk Kamonchanok; Hacksell Uli; Timmerman Henk; Brann Mark R; Weiner Dave M; Pardo Leonardo; Leurs Rob
Constitutively active mutants of the histamine H1 receptor suggest a conserved hydrophobic asparagine-cage that constrains the activation of class A G protein-coupled receptors.
Molecular pharmacology 2008;73(1):94-103.
2007: Gardell Luis R; Vanover Kimberly E; Pounds Linda; Johnson Robert W; Barido Richard; Anderson Gary T; Veinbergs Isaac; Dyssegaard Agnete; Brunmark Per; Tabatabaei Ali; Davis Robert E; Brann Mark R; Hacksell Uli; Bonhaus Douglas W
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
The Journal of pharmacology and experimental therapeutics 2007;322(2):862-70.
2007: Bakker R A; Nicholas M W; Smith T T; Burstein E S; Hacksell U; Timmerman H; Leurs R; Brann M R; Weiner D M
In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists.
The Journal of pharmacology and experimental therapeutics 2007;322(1):172-9.
2007: Lehmann Fredrik; Lake Lisa; Currier Erika A; Olsson Roger; Hacksell Uli; Luthman Kristina
Design, parallel synthesis and SAR of novel urotensin II receptor agonists.
European journal of medicinal chemistry 2007;42(2):276-85.
2006: Lehmann Fredrik; Pettersen Anna; Currier Erika A; Sherbukhin Vladimir; Olsson Roger; Hacksell Uli; Luthman Kristina
Novel potent and efficacious nonpeptidic urotensin II receptor agonists.
Journal of medicinal chemistry 2006;49(7):2232-40.
2005: Piu Fabrice; Gauthier Natalie K; Olsson Roger; Currier Erika A; Lund Birgitte W; Croston Glenn E; Hacksell Uli; Brann Mark R
Identification of novel subtype selective RAR agonists.
Biochemical pharmacology 2005;71(1-2):156-62.
2005: Lund Birgitte W; Piu Fabrice; Gauthier Natalie K; Eeg Anne; Currier Erika; Sherbukhin Vladimir; Brann Mark R; Hacksell Uli; Olsson Roger
Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
Journal of medicinal chemistry 2005;48(24):7517-9.
2005: Burstein E S; Ma J; Wong S; Gao Y; Pham E; Knapp A E; Nash N R; Olsson R; Davis R E; Hacksell U; Weiner D M; Brann M R
Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
The Journal of pharmacology and experimental therapeutics 2005;315(3):1278-87.
2005: Lehmann Fredrik; Currier Erika A; Olsson Roger; Hacksell Uli; Luthman Kristina
Isochromanone-based urotensin-II receptor agonists.
Bioorganic & medicinal chemistry 2005;13(8):3057-68.
2004: Weiner D M; Meltzer H Y; Veinbergs I; Donohue E M; Spalding T A; Smith T T; Mohell N; Harvey S C; Lameh J; Nash N; Vanover K E; Olsson R; Jayathilake K; Lee M; Levey A I; Hacksell U; Burstein E S; Davis R E; Brann M R
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
Psychopharmacology 2004;177(1-2):207-16.
2004: Vanover Kimberly E; Harvey Scott C; Son Thomas; Bradley Stefania Risso; Kold Henriette; Makhay Malath; Veinbergs Isaac; Spalding Tracy A; Weiner David M; Andersson Carl Magnus; Tolf Bo-Ragnar; Brann Mark R; Hacksell Uli; Davis Robert E
Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
The Journal of pharmacology and experimental therapeutics 2004;310(3):943-51.
2004: Bakker R A; Weiner D M; ter Laak T; Beuming T; Zuiderveld O P; Edelbroek M; Hacksell U; Timmerman H; Brann M R; Leurs R
8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist.
Molecular pharmacology 2004;65(3):538-49.
2004: Del Tredici Andria L; Schiffer Hans H; Burstein Ethan S; Lameh Jelveh; Mohell Nina; Hacksell Uli; Brann Mark R; Weiner David M
Pharmacology of polymorphic variants of the human 5-HT1A receptor.
Biochemical pharmacology 2004;67(3):479-90.
2003: Alder J Tracy; Hacksell Uli; Strange Philip G
Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino)tetralins at the 5-HT1A serotonin receptor.
British journal of pharmacology 2003;138(6):1129-39.
2002: Croston Glenn E; Olsson Roger; Currier Erika A; Burstein Ethan S; Weiner David; Nash Norman; Severance Daniel; Allenmark Stig G; Thunberg Linda; Ma Jian-Nong; Mohell Nina; O'Dowd Brian; Brann Mark R; Hacksell Uli
Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).
Journal of medicinal chemistry 2002;45(23):4950-3.
2002: Spalding Tracy A; Trotter Carol; Skjaerbaek Niels; Messier Terri L; Currier Erika A; Burstein Ethan S; Li Donghui; Hacksell Uli; Brann Mark R
Discovery of an ectopic activation site on the M(1) muscarinic receptor.
Molecular pharmacology 2002;61(6):1297-302.
2002: Hacksell Uli; Nash Norman; Burstein Ethan S; Piu Fabrice; Croston Glenn; Brann Mark R
Chemical genomics: massively parallel technologies for rapid lead identification and target validation.
Cytotechnology 2002;38(1-3):3-10.
2001: Weiner D M; Burstein E S; Nash N; Croston G E; Currier E A; Vanover K E; Harvey S C; Donohue E; Hansen H C; Andersson C M; Spalding T A; Gibson D F; Krebs-Thomson K; Powell S B; Geyer M A; Hacksell U; Brann M R
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
The Journal of pharmacology and experimental therapeutics 2001;299(1):268-76.
2001: Linnanen T; Brisander M; Unelius L; Rosqvist S; Nordvall G; Hacksell U; Johansson A M
Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists.
Journal of medicinal chemistry 2001;44(9):1337-40.
2000: Linnanen T; Brisander M; Unelius L; Sundholm G; Hacksell U; Johansson A M
Derivatives of (R)-1,11-methyleneaporphine: synthesis, structure, and interactions with G-protein coupled receptors.
Journal of medicinal chemistry 2000;43(7):1339-49.
2000: Sundquist S; Modiri A R; Nilsson B M; Hacksell U; Gillberg P G; Nilvebrant L
Pharmacological characterisation of the enantiomers of BM-5, a muscarinic partial agonist with opposed enantioselectivity between affinity and efficacy.
Pharmacology & toxicology 2000;86(1):44-50.
1999: Caldirola P; Chowdhury R; Unelius L; Mohell N; Hacksell U; Johansson A M
Novel derivatives of 3-(dipropylamino)chroman. Interactions with 5-HT1A and D2A receptors.
Bioorganic & medicinal chemistry letters 1999;9(11):1583-6.
1999: De Esch I J; Vollinga R C; Goubitz K; Schenk H; Appelberg U; Hacksell U; Lemstra S; Zuiderveld O P; Hoffmann M; Leurs R; Menge W M; Timmerman H
Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
Journal of medicinal chemistry 1999;42(7):1115-22.
1998: Malmberg A; Mohell N; Backlund Höök B; Johansson A M; Hacksell U; Nordvall G
Interactions of ligands with active and inactive conformations of the dopamine D2 receptor.
European journal of pharmacology 1998;346(2-3):299-307.
1998: Johansson G; Brisander M; Sundquist S; Hacksell U
Stereoisomers of 3-(2,3-dihydrobenzofuran-2-yl)quinuclidine: preparation and muscarinic receptor affinities.
Chirality 1998;10(9):813-20.
1997: Johansson G; Sundquist S; Nordvall G; Nilsson B M; Brisander M; Nilvebrant L; Hacksell U
Antimuscarinic 3-(2-furanyl)quinuclidin-2-ene derivatives: synthesis and structure-activity relationships.
Journal of medicinal chemistry 1997;40(23):3804-19.
1997: Jansen J M; Koehler K F; Hedberg M H; Johansson A M; Hacksell U; Nordvall G; Snyder J P
Molecular design using the minireceptor concept.
Journal of chemical information and computer sciences 1997;37(4):812-8.
1997: Yu H; Liu Y; Li H B; Martin A R; Hacksell U; Lewander T
Pharmacodynamic and pharmacokinetic studies in rats of S-8-(2-Furyl)- and R-8-phenyl-2-(di-n-propylamino) tetralin, two novel 5-HT1A receptor agonists in-vitro with different properties in-vivo.
The Journal of pharmacy and pharmacology 1997;49(2):169-77.
1996: Malmberg A; Höök B B; Johansson A M; Hacksell U
Novel (R)-2-amino-5-fluorotetralins: dopaminergic antagonists and inverse agonists.
Journal of medicinal chemistry 1996;39(22):4421-9.
1996: Höök B B; Cortizo L; Johansson A M; Westlind-Danielsson A; Mohell N; Hacksell U
Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
Journal of medicinal chemistry 1996;39(20):4036-43.
1996: Nordvall G; Sundquist S; Johansson G; Glas G; Nilvebrant L; Hacksell U
3-(2-Benzofuranyl)quinuclidin-2-ene derivatives: novel muscarinic antagonists.
Journal of medicinal chemistry 1996;39(17):3269-77.
1996: Yu H; Liu Y; Malmberg A; Mohell N; Hacksell U; Lewander T
Differential serotoninergic and dopaminergic activities of the (R)- and the (S)-enantiomers of 2-(di-n-propylamino)tetralin.
European journal of pharmacology 1996;303(3):151-62.
1996: Arborelius L; Nomikos G G; Hertel P; Salmi P; Grillner P; Höök B B; Hacksell U; Svensson T H
The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
Naunyn-Schmiedeberg's archives of pharmacology 1996;353(6):630-40.
1996: Vallgårda J; Appelberg U; Arvidsson L E; Hjorth S; Svensson B E; Hacksell U
trans-2-Aryl-N,N-dipropylcyclopropylamines: synthesis and interactions with 5-HT(1A) receptors.
Journal of medicinal chemistry 1996;39(7):1485-93.
1996: Yu H; Liu Y; Hacksell U; Lewander T
Oral cavity absorption of (R)-8-hydroxy-2-(di-n-propylamino)tetralin and (S)-8-acetyl-2-(di-n-propylamino)tetralin in the rat.
The Journal of pharmacy and pharmacology 1996;48(1):41-5.
1996: Hillver S E; Björk L; Höök B B; Cortizo L; Nordvall G; Johansson A M; Ertan A; Csöregh I; Johansson L; Lewander T; Hacksell U
Synthesis and pharmacology of the enantiomers of UH301: opposing interactions with 5-HT1A receptors.
Chirality 1996;8(8):531-44.
1996: Nordvall G; Nilsson B M; Sundquist S; Johansson G; Glas G; Nilvebrant L; Hacksell U
3-Heteroarylquinuclidin-2-ene derivatives as muscarinic antagonists: synthesis, structure-activity relationships and molecular modelling.
Progress in brain research 1996;109():141-5.
1996: Nomikos G G; Arborelius L; Höök B B; Hacksell U; Svensson T H
The 5-HT1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(5):541-54.
1995: Arborelius L; Nomikos G G; Grillner P; Hertel P; Höök B B; Hacksell U; Svensson T H
5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram.
Naunyn-Schmiedeberg's archives of pharmacology 1995;352(2):157-65.
1995: Hedberg M H; Johansson A M; Nordvall G; Yliniemelä A; Li H B; Martin A R; Hjorth S; Unelius L; Sundell S; Hacksell U
(R)-11-hydroxy- and (R)-11-hydroxy-10-methylaporphine: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions.
Journal of medicinal chemistry 1995;38(4):647-58.
1995: Nilsson B M; Sundquist S; Johansson G; Nordvall G; Glas G; Nilvebrant L; Hacksell U
3-Heteroaryl-substituted quinuclidin-3-ol and quinuclidin-2-ene derivatives as muscarinic antagonists. Synthesis and structure-activity relationships.
Journal of medicinal chemistry 1995;38(3):473-87.
1995: Liljebris C; Selén G; Resul B; Stjernschantz J; Hacksell U
Derivatives of 17-phenyl-18,19,20-trinorprostaglandin F2 alpha isopropyl ester: potential antiglaucoma agents.
Journal of medicinal chemistry 1995;38(2):289-304.
1995: Liu Y; Yu H; Mohell N; Nordvall G; Lewander T; Hacksell U
Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.
Journal of medicinal chemistry 1995;38(1):150-60.
1995: Hacksell U; Nilsson B M; Nordvall G; Johansson G; Sundquist S; Nilvebrant L
Quinuclidin-2-ene-based muscarinic antagonists.
Life sciences 1995;56(11-12):831-6.
1995: Lambrecht G; Gross J; Hacksell U; Hermanni U; Hildebrandt C; Hou X; Moser U; Nilsson B M; Pfaff O; Waelbroeck M
The design and pharmacology of novel selective muscarinic agonists and antagonists.
Life sciences 1995;56(11-12):815-22.
1994: Malmberg A; Nordvall G; Johansson A M; Mohell N; Hacksell U
Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors.
Molecular pharmacology 1994;46(2):299-312.
1994: Johansson A M; Grol C J; Karlén A; Hacksell U
Dopamine D2 receptor agonists: an analysis of indirect models.
Drug design and discovery 1994;11(2):159-74.
1994: Arborelius L; Höök B B; Hacksell U; Svensson T H
The 5-HT1A receptor antagonist (S)-UH-301 blocks the qR)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the rat.
Journal of neural transmission. General section 1994;96(3):179-86.
1993: Liu Y; Yu H; Svensson B E; Cortizo L; Lewander T; Hacksell U
Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptors.
Journal of medicinal chemistry 1993;36(26):4221-9.
1993: Arborelius L; Nomikos G G; Hacksell U; Svensson T H
(R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex.
Acta physiologica Scandinavica 1993;148(4):465-6.
1993: Jansen J M; Karlén A; Grol C J; Hacksell U
Conformational properties of melatonin and two conformationally restricted agonists: a molecular mechanics and NMR spectroscopic study.
Drug design and discovery 1993;10(2):115-33.
1993: Arborelius L; Chergui K; Murase S; Nomikos G G; Höök B B; Chouvet G; Hacksell U; Svensson T H
The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons.
Naunyn-Schmiedeberg's archives of pharmacology 1993;347(4):353-62.
1993: Nordvall G; Hacksell U
Binding-site modeling of the muscarinic m1 receptor: a combination of homology-based and indirect approaches.
Journal of medicinal chemistry 1993;36(8):967-76.
1993: Yu H; Liu Y; Hacksell U; Lewander T
(R)- and (S)-8-acetyl-2-(dipropylamino)tetralin (LY-41): two novel 5-HT1A receptor agonists.
European journal of pharmacology 1993;231(1):69-76.
1993: Hacksell U; Liu Y; Yu H; Vallgårda J; Höök B B; Johansson A M; Lewander T
Neuromedicinal chemistry of 5-HT1A-receptor agonists and antagonists.
Drug design and discovery 1993;9(3-4):287-97.
1993: Höök B B; Johansson A M; Hjorth S; Sundell S; Hacksell U
Synthesis of (+)-(R)- and (-)-(S)-5-hydroxy-2-methyl-2-dipropylaminotetralin: effects on rat hippocampal output of 5-HT, 5-HIAA, and DOPAC as determined by in vivo microdialysis.
Chirality 1993;5(3):112-9.
1992: Nilsson B M; Vargas H M; Hacksell U
Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
Journal of medicinal chemistry 1992;35(17):3270-9.
1992: Nilsson B M; Vargas H M; Hacksell U
Amide, urea, and carbamate analogues of the muscarinic agent [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride.
Journal of medicinal chemistry 1992;35(15):2787-98.
1992: Björk L; Fredriksson A; Hacksell U; Lewander T
Effects of (R)-8-OH-DPAT and the enantiomers of UH-301 on motor activities in the rat: antagonism of (R)-8-OH-DPAT-induced effects.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1992;2(2):141-7.
1992: Nordvall G; Sundquist S; Glas G; Gogoll A; Nilvebrant L; Hacksell U
Analogues of the muscarinic agent 2'-methylspiro[1-azabicyclo[2.2.2]octane-3,4'-[1,3]dioxolane]: synthesis and pharmacology.
Journal of medicinal chemistry 1992;35(9):1541-50.
1992: Nilsson B M; Vargas H M; Ringdahl B; Hacksell U
Phenyl-substituted analogues of oxotremorine as muscarinic antagonists.
Journal of medicinal chemistry 1992;35(2):285-94.
1992: Messer W S; Ngur D O; Abuh Y F; Dokas L A; Ting S M; Hacksell U; Nilsson B M; Dunbar P G; Hoss W
Stereoselective binding and activity of oxotremorine analogs at muscarinic receptors in rat brain.
Chirality 1992;4(8):463-8.
1992: Nilsson B M; De Boer P; Grol C J; Hacksell U
An improved synthesis of the enantiomers of BM-5 and their effects on the central in vivo release of acetylcholine.
Chirality 1992;4(6):367-76.
1991: Johansson C E; Meyerson B J; Hacksell U
The novel 5-HT1A receptor antagonist (S)-UH-301 antagonizes 8-OH-DPAT-induced effects on male as well as female rat copulatory behaviour.
European journal of pharmacology 1991;202(1):81-7.
1991: Björk L; Lindgren S; Hacksell U; Lewander T
(S)-UH-301 antagonizes (R)-8-OH-DPAT-induced cardiovascular effects in the rat.
European journal of pharmacology 1991;199(3):367-70.
1991: Björk L; Cornfield L J; Nelson D L; Hillver S E; Andén N E; Lewander T; Hacksell U
Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects.
The Journal of pharmacology and experimental therapeutics 1991;258(1):58-65.
1991: Grol C J; Nordvall G; Johansson A M; Hacksell U
5-Oxygenated N-alkyl- and N,N-Dialkyl-2-amino-1-methyltetralins. Effects of structure and stereochemistry on dopamine-D2-receptor affinity.
The Journal of pharmacy and pharmacology 1991;43(7):481-5.
1991: Cornfield L J; Lambert G; Arvidsson L E; Mellin C; Vallgårda J; Hacksell U; Nelson D L
Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase.
Molecular pharmacology 1991;39(6):780-7.
1991: Mellin C; Vallgårda J; Nelson D L; Björk L; Yu H; Andén N E; Csöregh I; Arvidsson L E; Hacksell U
A 3-D model for 5-HT1A-receptor agonists based on stereoselective methyl-substituted and conformationally restricted analogues of 8-hydroxy-2-(dipropylamino)tetralin.
Journal of medicinal chemistry 1991;34(2):497-510.
1990: Lundkvist J R; Vargas H M; Caldirola P; Ringdahl B; Hacksell U
Resolved pyrrolidine, piperidine, and perhydroazepine analogues of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
Journal of medicinal chemistry 1990;33(12):3182-9.
1990: Johansson A M; Fredriksson K; Hacksell U; Grol C J; Svensson K; Carlsson A; Sundell S
Synthesis and pharmacology of the enantiomers of cis-7-hydroxy-3-methyl-2-(dipropylamino)tetralin.
Journal of medicinal chemistry 1990;33(10):2925-9.
1990: Hillver S E; Björk L; Li Y L; Svensson B; Ross S; Andén N E; Hacksell U
(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HT1A-receptor antagonist.
Journal of medicinal chemistry 1990;33(6):1541-4.
1990: Nilsson B M; Ringdahl B; Hacksell U
Beta-lactam analogues of oxotremorine. 3- and 4-methyl-substituted 2-azetidinones.
Journal of medicinal chemistry 1990;33(2):580-4.
1990: Karlsson A; Björk L; Pettersson C; Andén N E; Hacksell U
(R)- and (S)-5-hydroxy-2-(dipropylamino)tetralin (5-OH DPAT): assessment of optical purities and dopaminergic activities.
Chirality 1990;2(2):90-5.
1989: Liu Y; Mellin C; Björk L; Svensson B; Csöregh I; Helander A; Kenne L; Andén N E; Hacksell U
(R)- and (S)-5,6,7,8-tetrahydro-1-hydroxy-N,N-dipropyl-9H-benzocyclohepten- 8-ylamine. Stereoselective interactions with 5-HT1A receptors in the brain.
Journal of medicinal chemistry 1989;32(10):2311-8.
1989: Lundkvist J R; Ringdahl B; Hacksell U
Conformationally restricted analogues of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
Journal of medicinal chemistry 1989;32(4):863-9.
1989: Björk L; Höök B B; Nelson D L; Andén N E; Hacksell U
Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
Journal of medicinal chemistry 1989;32(4):779-83.
1989: Karlén A; Helander A; Kenne L; Hacksell U
Topography and conformational preferences of 6,7,8,9-tetrahydro-1-hydroxy-N,N-dipropyl-5H-benzocyclohepten-6- ylamin e. A rationale for the dopaminergic inactivity.
Journal of medicinal chemistry 1989;32(4):765-74.
1989: Hacksell U; Mellin C
Stereoselectivity of nicotinic receptors.
Progress in brain research 1989;79():95-100.
1989: Karlén A; Hacksell U; Helander A; Kenne L
Why are benzocycloheptenylamines inactive as dopamine D2-receptor agonists?
Progress in clinical and biological research 1989;291():281-4.
1988: Mellin C; Björk L; Karlén A; Johansson A M; Sundell S; Kenne L; Nelson D L; Andén N E; Hacksell U
Central dopaminergic and 5-hydroxytryptaminergic effects of C3-methylated derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin.
Journal of medicinal chemistry 1988;31(6):1130-40.
1988: Nilsson B M; Ringdahl B; Hacksell U
Derivatives of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
Journal of medicinal chemistry 1988;31(3):577-82.
1988: Arvidsson L E; Johansson A M; Hacksell U; Nilsson J L; Svensson K; Hjorth S; Magnusson T; Carlsson A; Lindberg P; Andersson B
N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: novel central 5-hydroxytryptamine receptor agonists.
Journal of medicinal chemistry 1988;31(1):92-9.
1988: Arvidsson L E; Karlén A; Norinder U; Kenne L; Sundell S; Hacksell U
Structural factors of importance for 5-hydroxytryptaminergic activity. Conformational preferences and electrostatic potentials of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and some related agents.
Journal of medicinal chemistry 1988;31(1):212-21.
1987: Björk L; Mellin C; Hacksell U; Andén N E
Effects of the C3-methylated derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on central 5-hydroxytryptamine receptors.
European journal of pharmacology 1987;143(1):55-63.
1987: Arvidsson L E; Johansson A M; Hacksell U; Nilsson J L; Svensson K; Hjorth S; Magnusson T; Carlsson A; Andersson B; Wikström H
(+)-cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist.
Journal of medicinal chemistry 1987;30(11):2105-9.
1987: Johansson A M; Nilsson J L; Karlén A; Hacksell U; Sanchez D; Svensson K; Hjorth S; Carlsson A; Sundell S; Kenne L
C1- and C3-methyl-substituted derivatives of 7-hydroxy-2-(di-n-propylamino)tetralin: activities at central dopamine receptors.
Journal of medicinal chemistry 1987;30(10):1827-37.
1987: Johansson A M; Nilsson J L; Karlén A; Hacksell U; Svensson K; Carlsson A; Kenne L; Sundell S
C3-methylated 5-hydroxy-2-(dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation.
Journal of medicinal chemistry 1987;30(7):1135-44.
1987: Mellin C; Liu Y; Hacksell U; Björk L; Andén N E
A C2-methylated derivative of the 5-hydroxy-tryptamine-receptor agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH DPAT).
Acta pharmaceutica Suecica 1987;24(4):153-60.
1987: Krotowska A; Nordvall G; Mellin C; Johansson A M; Hacksell U
Dopamine D2-receptor affinities of resolved C1-dimethylated 2-aminotetralins.
Acta pharmaceutica Suecica 1987;24(4):145-52.
1986: Johansson A M; Karlén A; Grol C J; Sundell S; Kenne L; Hacksell U
Dopaminergic 2-aminotetralins: affinities for dopamine D2-receptors, molecular structures, and conformational preferences.
Molecular pharmacology 1986;30(3):258-69.
1986: Karlén A; Johansson A M; Kenne L; Arvidsson L E; Hacksell U
Conformational analysis of the dopamine-receptor agonist 5-hydroxy-2-(dipropylamino)tetralin and its C(2)-methyl-substituted derivative.
Journal of medicinal chemistry 1986;29(6):917-24.
1986: Hacksell U; Arvidsson L E; Johansson A M; Nilsson J L; Sanchez D; Lindberg P; Wikström H; Svensson K; Hjorth S; Carlsson A
Indirect central 5-hydroxytryptaminergic actions of methoxy substituted 2-aminotetralin derivatives.
Acta pharmaceutica Suecica 1986;23(2):77-90.
1985: Hacksell U; Arvidsson L E; Johansson A M; Nilsson J L; Sanchez D; Andersson B; Lindberg P; Wikström H; Hjorth S; Svensson K
5-Hydroxy-2-methyl-2-(di-n-propylamino)tetralin: synthesis and central pharmacological effects.
Acta pharmaceutica Suecica 1985;22(2):65-74.
1984: Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson L E; Johansson A M; Thorberg S O; Nilsson J L; Svensson K; Hjorth S
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
Journal of medicinal chemistry 1984;27(8):1030-6.
1984: Arvidsson L E; Hacksell U; Johansson A M; Nilsson J L; Lindberg P; Sanchez D; Wikström H; Svensson K; Hjorth S; Carlsson A
8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
Journal of medicinal chemistry 1984;27(1):45-51.
1983: Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson L E; Johansson A; Nilsson J L
The search for selective dopaminergic autoreceptor agonists.
Journal of neural transmission. Supplementum 1983;18():131-7.
1983: Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson L E; Johansson A
Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.
Psychopharmacology 1983;81(2):89-99.
1982: Wikström H; Sanchez D; Lindberg P; Arvidsson L E; Hacksell U; Johansson A; Nilsson J L; Hjorth S; Carlsson A
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
Journal of medicinal chemistry 1982;25(8):925-31.
1981: Hacksell U; Arvidsson L E; Svensson U; Nilsson J L; Sanchez D; Wikström H; Lindberg P; Hjorth S; Carlsson A
3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity.
Journal of medicinal chemistry 1981;24(12):1475-82.
1981: Ahlenius S; Larsson K; Svensson L; Hjorth S; Carlsson A; Lindberg P; Wikström H; Sanchez D; Arvidsson L E; Hacksell U; Nilsson J L
Effects of a new type of 5-HT receptor agonist on male rat sexual behavior.
Pharmacology, biochemistry, and behavior 1981;15(5):785-92.
1981: Arvidsson L E; Hacksell U; Nilsson J L; Hjorth S; Carlsson A; Lindberg P; Sanchez D; Wikstrom H
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
Journal of medicinal chemistry 1981;24(8):921-3.
1981: Hacksell U; Arvidsson L E; Svensson U; Nilsson J L; Wikström H; Lindberg P; Sanchez D; Hjorth S; Carlsson A; Paalzow L
Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
Journal of medicinal chemistry 1981;24(4):429-34.
1981: Hjorth S; Carlsson A; Wikström H; Lindberg P; Sanchez D; Hacksell U; Arvidsson L E; Svensson U; Nilsson J L
3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors.
Life sciences 1981;28(11):1225-38.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Uli Hacksell

Research Profile (preview)

Living Beings

Chemicals & Drugs

Concepts & Ideas

Anatomy

Activities & Behaviors

Genes & Molecular Sequences

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Uli Hacksell (preview)

All Publications